APR 23, 2020 11:39 AM PDT

Dual Inhibition from One Chemotherapy

WRITTEN BY: Jasper Cantrell

Acute Myeloid Leukemia, or AML, is an aggressive blood cancer with a poor 5-year prognosis. The primary chemotherapeutic targets are usually receptor tyrosine kinases. One such kinase is called FLT3. FLT3 is a receptor tyrosine kinase that initiates several downstream pathways involved in cellular proliferation, including Akt, mTOR, and several others. Specific mutations called internal tandem repeats, or FLT3-ITD, cause uncontrolled activation of FLT3 and its downstream pathways. This uncontrolled activation quickly leads to cancer transformation. While several inhibitors exist for FLT3, they all suffer from minor complications, and cancers treated with them were prone to generate resistance against them.

A group from the United Kingdom began an investigation into a new dual inhibitor, CCT241736, that seemed to overcome the issues seen in other FLT3 inhibitors. This new compound had been shown previously to bind to both FLT3, and another kinase called aurora kinase. The aurora kinase is involved in mitosis, and inhibition can result in cell cycle arrest, which can induce cell death. They began their testing by measuring CCT241736 against other aurora kinase inhibitors on AML cell lines in vitro. Standard inhibitors exhibited mixed results, where CCT241736 produced proper cell cycle arrest that induced cell death. This result proved its efficacy in selective inhibition of aurora kinase over other inhibitors.

Next, they decided to examine CCT241736s FLT3 inhibitory abilities. It was shown in previous work that the resistance developed by cancer cells was due to secondary mutations on top of the original ITD. Testing CCT241736 on a screen of FLT3 inhibitor-resistant AML cell lines revealed that CCT241736 was tens of times more potent in its suppression of growth when compared to other FLT3 inhibitors. Mouse experiments confirmed this, and no resistance developed against CCT241736 even after 107 days of treatment. This data suggests that CCT241736 uniquely interacts with FLT3 that, that prevents resistance by new mutations seen in other inhibitors.

The dual inhibitory capabilities of CCT241736 FLT3 and aurora kinase make it a great candidate for possible chemotherapy. Its oral bioavailability and low blood clearance are big pluses in actual treatment as well. The actual mechanism by which CCT241736 inhibits both FLT3 and aurora kinase still needs to be investigated. However, the results of this paper make CFT241736 an attractive target for future chemotherapy research.

Sources: Blood Advances, OncLiveTV
 

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
JUL 23, 2020
Clinical & Molecular DX
Prostate Cancer: To Treat or Not to Treat
JUL 23, 2020
Prostate Cancer: To Treat or Not to Treat
After a prostate cancer diagnosis, urologists do not always initiate immediate clinical intervention. In those with Low- ...
JUL 27, 2020
Cancer
Identifying Tumor Cells in the Blood with Artificial Intelligence
JUL 27, 2020
Identifying Tumor Cells in the Blood with Artificial Intelligence
Cancer diagnostics is an area of keen interest in the fight against cancer. Cancer often slips by routine checkups and v ...
AUG 03, 2020
Cell & Molecular Biology
Gut Microbes & Diet Change the Behavior of a Cancer-Driving Protein
AUG 03, 2020
Gut Microbes & Diet Change the Behavior of a Cancer-Driving Protein
Clinicians and researchers have long wondered why cancer is the small intestine is rare while it's so common in the colo ...
AUG 21, 2020
Cancer
Investigating Cancer's Metabolism for a New Drug Target
AUG 21, 2020
Investigating Cancer's Metabolism for a New Drug Target
Cancer cells are quite similar to normal cells in many ways, but it’s the small differences that really matter. On ...
AUG 21, 2020
Immunology
Cancer Feels the STING
AUG 21, 2020
Cancer Feels the STING
Researchers have discovered a protein that can amplify immune reactions against tumors. The stimulator of interferon gen ...
SEP 02, 2020
Cancer
New contrast dyes detect cancer using tatoo ink
SEP 02, 2020
New contrast dyes detect cancer using tatoo ink
Researchers have developed new cancer detection agents in the form of contrast dyes from tattoo ink. The results of thes ...
Loading Comments...